Malak Munir, John L Vaughn, Sravani Rimmalapudi, Narendranath Epperla
{"title":"Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras.","authors":"Malak Munir, John L Vaughn, Sravani Rimmalapudi, Narendranath Epperla","doi":"10.1038/s41408-026-01648-y","DOIUrl":"10.1038/s41408-026-01648-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silvia Ferrari, Francesco Ballardini, Andrea Rossi, Anna Grassi, Chiara Pavoni, Monica Rondi, Paolo Fruscella, Andrea Gianatti, Giuseppe Gritti, Anna Maria Barbui, Federico Lussana, Alessandro Rambaldi
{"title":"The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma.","authors":"Silvia Ferrari, Francesco Ballardini, Andrea Rossi, Anna Grassi, Chiara Pavoni, Monica Rondi, Paolo Fruscella, Andrea Gianatti, Giuseppe Gritti, Anna Maria Barbui, Federico Lussana, Alessandro Rambaldi","doi":"10.1038/s41408-026-01630-8","DOIUrl":"10.1038/s41408-026-01630-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hamlet Gasoyan,Shahzad Raza,Michael B. Rothberg,Jeffrey D. Kovach,Nicholas J. Casacchia,Jason Valent,Faiz Anwer
{"title":"Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies","authors":"Hamlet Gasoyan,Shahzad Raza,Michael B. Rothberg,Jeffrey D. Kovach,Nicholas J. Casacchia,Jason Valent,Faiz Anwer","doi":"10.1038/s41408-026-01645-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01645-1","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"35 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah A. Bird,Marco P. Licciardello,Salomon Morales,Mara Mandelia,Enze Liu,Yakinthi Chrisochoidou,James Smith,Amy Wilson,Jack Cheung,Shannon Martin,Yigen Li,Fernando J. Sialana,Brian A. Walker,Paul A. Clarke,Charlotte Pawlyn
{"title":"SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models","authors":"Sarah A. Bird,Marco P. Licciardello,Salomon Morales,Mara Mandelia,Enze Liu,Yakinthi Chrisochoidou,James Smith,Amy Wilson,Jack Cheung,Shannon Martin,Yigen Li,Fernando J. Sialana,Brian A. Walker,Paul A. Clarke,Charlotte Pawlyn","doi":"10.1038/s41408-026-01632-6","DOIUrl":"https://doi.org/10.1038/s41408-026-01632-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"41 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation","authors":"Wan-Hsuan Lee, Xavier Cheng-Hong Tsai, Chien-Chin Lin, Feng-Ming Tien, Min-Yen Lo, Yu-Sung Chang, Tai-Chung Tseng, Tai-Chung Huang, Bor-Sheng Ko, Ming Yao, Yen-Ling Peng, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Szu-Hwei Lee, Chi-Yuan Yao, Chang-Tsu Yuan, Shan-Chi Yu, Hwei-Fang Tien, Hsin-An Hou, Wen-Chien Chou","doi":"10.1038/s41408-026-01637-1","DOIUrl":"https://doi.org/10.1038/s41408-026-01637-1","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for myelodysplastic neoplasms/syndromes (MDS), but post-transplant relapse continues to limit long-term survival. Reliable identification of patients at high relapse risk remains lacking. A cohort of 192 patients with MDS or AML undergoing allo-HSCT was analyzed to assess the prognostic significance of measurable residual disease (MRD) by next-generation sequencing (NGS) and multiparametric flow cytometry (MFC). MRD was assessed longitudinally at predefined time points; NGS-MRD positivity was defined as persistence of disease-associated mutations (excluding DNMT3A, TET2, and ASXL1) at a variant allele frequency >0.01%. At 1 month post-transplantation, NGS-MRD positivity was detected in 15.7% of patients and was strongly associated with higher relapse risk and inferior survival outcomes. The 6-month cumulative incidence of relapse was significantly higher in MRD-positive vs. MRD-negative patients (64.7% vs. 23.5%), with markedly shorter relapse-free survival (5.3 vs. 85.3 months) and overall survival (13.4 vs. 73.7 months) (all P < 0.05). In multivariable analysis, 1-month NGS-MRD positivity remained an independent relapse and mortality predictor. MFC-MRD demonstrated prognostic value only at later time points. Early post-transplantation NGS-MRD may be a dominant prognostic biomarker and support its integration into MRD-guided, risk-adapted post-transplantation management strategies.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"10 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
